- Home
- BCLI vs CSCI Comparison
BCLI vs CSCI Comparison
Compare BCLI & CSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- CSCI
- Stock Information
- Founded
- BCLI 2000
- CSCI 1990
- Country
- BCLI United States
- CSCI Canada
- Employees
- BCLI N/A
- CSCI N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- CSCI
- Sector
- BCLI Health Care
- CSCI
- Exchange
- BCLI Nasdaq
- CSCI NYSE
- Market Cap
- BCLI 9.8M
- CSCI 10.6M
- IPO Year
- BCLI N/A
- CSCI 1996
- Fundamental
- Price
- BCLI $1.16
- CSCI $3.47
- Analyst Decision
- BCLI Strong Buy
- CSCI
- Analyst Count
- BCLI 1
- CSCI 0
- Target Price
- BCLI $30.00
- CSCI N/A
- AVG Volume (30 Days)
- BCLI 412.8K
- CSCI 1.9K
- Earning Date
- BCLI 08-13-2025
- CSCI 08-12-2025
- Dividend Yield
- BCLI N/A
- CSCI N/A
- EPS Growth
- BCLI N/A
- CSCI N/A
- EPS
- BCLI N/A
- CSCI N/A
- Revenue
- BCLI N/A
- CSCI $9,030,000.00
- Revenue This Year
- BCLI N/A
- CSCI N/A
- Revenue Next Year
- BCLI N/A
- CSCI N/A
- P/E Ratio
- BCLI N/A
- CSCI N/A
- Revenue Growth
- BCLI N/A
- CSCI 36.51
- 52 Week Low
- BCLI $0.72
- CSCI $1.96
- 52 Week High
- BCLI $6.45
- CSCI $7.54
- Technical
- Relative Strength Index (RSI)
- BCLI 49.98
- CSCI N/A
- Support Level
- BCLI $1.02
- CSCI N/A
- Resistance Level
- BCLI $1.32
- CSCI N/A
- Average True Range (ATR)
- BCLI 0.09
- CSCI 0.00
- MACD
- BCLI -0.00
- CSCI 0.00
- Stochastic Oscillator
- BCLI 46.67
- CSCI 0.00
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.